Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Proportion of participants who did not have a confirmed relapse

Time frame: At 12 and 24 months

Number of gadolinium enhancing (GdE) T1 lesions

Time frame: At month 6 and month 12

Number of new or newly enlarging hyperintense lesions on T2 magnetic resonance imaging (MRI) sequences

Time frame: At 6, 12, 18, and 24 months

Incidence of treatment-emergent adverse events (TEAEs) over the treatment period and over the post-treatment follow-up period

Time frame: Up to 87 months

Incidence of adverse event of special interests (AESIs) over the treatment period and over the post-treatment follow-up period

Time frame: Up to 87 months

Adverse events (AEs) leading to discontinuation over the treatment period and over the post-treatment follow-up period

Time frame: Up to 87 months

Steady state plasma concentrations of ozanimod

Time frame: At day 90

Steady state plasma concentrations of the primary active metabolite CC112273

Time frame: At day 90

Change from baseline pharmacodynamics (PD) biomarkers of absolute lymphocyte count

Time frame: At day 90 and throughout the study up to 24 months